Skip to main content

Client News

Abivax publishes novel data with respect to obefazimod’s anti-inflammatory mechanism of action

5th January 2023

LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles

3rd January 2023

Mainz Biomed provides year-end 2022 corporate review

3rd January 2023

Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

3rd January 2023

Destiny Pharma announces year end Trading Update Good progress across all key projects in 2022

22nd December 2022

InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19

21st December 2022

Abivax receives FDA agreement on pediatric development plan with obefazimod in IBD

20th December 2022

Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

20th December 2022

Rentschler Biopharma awarded Chiesi Supplier Award

19th December 2022

Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform

16th December 2022